HORAN Wealth LLC Boosts Stock Holdings in AbbVie Inc. $ABBV

HORAN Wealth LLC lifted its position in shares of AbbVie Inc. (NYSE:ABBV) by 51.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 24,350 shares of the company’s stock after acquiring an additional 8,313 shares during the period. AbbVie makes up approximately 0.9% of HORAN Wealth LLC’s portfolio, making the stock its 21st largest position. HORAN Wealth LLC’s holdings in AbbVie were worth $5,638,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Brighton Jones LLC lifted its stake in AbbVie by 17.4% during the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock valued at $4,072,000 after acquiring an additional 3,401 shares during the period. Revolve Wealth Partners LLC grew its stake in shares of AbbVie by 72.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after acquiring an additional 3,064 shares during the period. Joel Isaacson & Co. LLC raised its holdings in shares of AbbVie by 1.2% during the second quarter. Joel Isaacson & Co. LLC now owns 6,773 shares of the company’s stock valued at $1,257,000 after purchasing an additional 79 shares during the last quarter. BankPlus Trust Department raised its holdings in shares of AbbVie by 3.3% during the second quarter. BankPlus Trust Department now owns 27,113 shares of the company’s stock valued at $5,033,000 after purchasing an additional 855 shares during the last quarter. Finally, Friedenthal Financial lifted its position in AbbVie by 3,152.5% during the second quarter. Friedenthal Financial now owns 1,301 shares of the company’s stock valued at $241,000 after purchasing an additional 1,261 shares during the period. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Price Performance

NYSE:ABBV opened at $217.04 on Thursday. The firm has a market capitalization of $383.59 billion, a price-to-earnings ratio of 164.42, a price-to-earnings-growth ratio of 0.93 and a beta of 0.35. The business has a fifty day moving average price of $223.99 and a 200-day moving average price of $219.14. AbbVie Inc. has a one year low of $164.39 and a one year high of $244.81.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The business had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. During the same quarter in the prior year, the business posted $2.16 earnings per share. The business’s quarterly revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities research analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have commented on ABBV. Evercore ISI reaffirmed an “outperform” rating and issued a $228.00 target price on shares of AbbVie in a research report on Wednesday. Piper Sandler restated an “overweight” rating and issued a $289.00 price target (up from $284.00) on shares of AbbVie in a research note on Wednesday, November 5th. DZ Bank lowered AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective for the company. in a report on Tuesday, November 4th. Berenberg Bank set a $275.00 price objective on AbbVie in a research report on Tuesday, January 20th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a report on Wednesday, January 21st. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and a consensus price target of $251.50.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q4 beat and raised FY outlook — AbbVie reported Q4 adjusted EPS of $2.71 and revenue of $16.62B, topping estimates; management gave 2026 adjusted EPS guidance of $14.37–$14.57, above consensus, supporting the view of durable profit growth. Article Title
• Positive Sentiment: Immunology momentum — Strong demand for Skyrizi (+32% Y/Y) and Rinvoq (+29% Y/Y) drove the beat and are cited by management as the engine of revenue growth, partially offsetting Humira declines. Analysts point to continued upside from these franchises. Article Title
• Positive Sentiment: Rinvoq label expansion in progress — AbbVie submitted regulatory applications for Rinvoq (upadacitinib) in vitiligo (FDA/EMA), a meaningful new indication if approved that could support longer‑term growth. Article Title
• Neutral Sentiment: Analyst positioning mixed — Some firms (e.g., Evercore) kept bullish ratings citing immunology strength and neurology upside, while others are pausing to re‑assess targets; this is keeping trading volatile. Article Title
• Negative Sentiment: Q1 guidance missed expectations — AbbVie issued Q1 2026 EPS guidance of $2.97–$3.01 versus a ~ $3.11 consensus, and revenue guidance came in below forecasts, prompting concern about near‑term growth momentum. (Company guidance update)
• Negative Sentiment: Segment weakness and diversification worries — Aesthetics (Botox/Cosmetics) and parts of oncology showed declines and some reports flag that growth is concentrated in immunology; commentators warn the company may lean on M&A/IPR&D to sustain growth. Article Title
• Negative Sentiment: Investor skepticism on Rinvoq contribution and valuation questions — Some coverage highlights that Rinvoq’s role vs. expectations (and valuation implications for the company) remains under scrutiny despite the drug’s growth. Article Title

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.